– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer...
Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1...
Media Release First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response...
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line...
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of...
Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for...
Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in...
Glen Rock, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in...
--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on...
MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing...
- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of...
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
- Median Overall Survival for GPS Combination (GPS in Combination with Keytruda) was 18.4 Months Compared to 13.8 months in...
KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"),...
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid...
Company completed a public offering for aggregate gross proceeds of $16.8 millionMajority of clinical sites now open in clinical study...
Media ReleaseCOPENHAGEN, Denmark; November 10, 2022 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de...
Reports progress towards global supply chain development Ended the third quarter of 2022 with cash, cash equivalents and marketable securities...
Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics...
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating...